Skip to main content

Advertisement

SpringerLink
Log in

The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab

  • Mini-Review
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

The physical presentation of psoriasis and its impact on health-related quality of life (HRQoL) varies greatly between patients as well as over the course of the disease. A number of instruments have been developed for evaluating disease severity and its impact on HRQoL, the best known being the Psoriasis Area and Severity Index (PASI). HRQoL is most commonly evaluated using the Dermatology Life Quality Index (DLQI) and/or the Short-Form-36 Health Survey (SF-36). The exact correlation between the reduction of skin symptoms upon therapy and changes of HRQoL is not known. Since improvement of HRQoL is being established as an independent goal of psoriasis therapy, a better understanding of the relationship between skin symptoms and HRQoL during treatment will likely influence not only disease concepts but also physicians treatment decisions. Based on a selective review of the literature, this paper focuses on recent insight obtained from clinical trials with infliximab on the correlation between skin clearance and changes of HRQoL in psoriasis and compares these findings with results from studies with other biologics. Together these data indicate that despite the lack of a direct correlation between absolute PASI and DLQI values, significant reductions of PASI are likely to correlate with significant improvements of HRQoL. There is also evidence, that large improvements of HRQoL as currently discussed as treatment goals in psoriasis are primarily achieved in patients with an at least 75% reduction of their PASI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216:366–372

    Article  PubMed  CAS  Google Scholar 

  2. Brandt J, Braun J (2006) Anti-TNF alpha agents in the treatment of psoriatic arthritis. Expert Opin Biol Ther 6:99–107

    Article  PubMed  CAS  Google Scholar 

  3. de Jong EM, Seegers BA, Gulinck MK, Bozeeman JB, van de Kerkhof PC (1996) Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1, 728 patients. Dermatology 193:300–303

    Article  PubMed  Google Scholar 

  4. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB (2005) Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 152:954–960

    Article  PubMed  CAS  Google Scholar 

  5. Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64(suppl 2):ii65–ii68

    Article  PubMed  Google Scholar 

  6. Finlay AY (2005) Current severe psoriasis and the rule of tens. Br J Dermatol 152:861–867

    Article  PubMed  CAS  Google Scholar 

  7. Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210–216

    Article  PubMed  CAS  Google Scholar 

  8. Fortune DG, Main CJ, O’Sullivan TM, Griffiths CEM (1997) Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 137:755–760

    Article  PubMed  CAS  Google Scholar 

  9. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A, Efalizumab Study Group (2003) Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290:3073–3080 (Erratum in: JAMA 2004 Mar 3;291: 1070)

    Article  PubMed  CAS  Google Scholar 

  10. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51:534–542

    Article  PubMed  Google Scholar 

  11. Griffiths CEM, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263–271

    Article  PubMed  CAS  Google Scholar 

  12. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY (2005) Translating the science of quality of life into practice: what do dermatology quality of life index scores mean? J Invest Dermatol 125:659–664

    Article  PubMed  CAS  Google Scholar 

  13. Husted JA, Gladman DD, Long JA, Farewell VT (1995) A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 13:439–443

    PubMed  CAS  Google Scholar 

  14. Katugampola RP, Lewis VJ, Finlay AY (2007) The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 156:945–950

    Article  PubMed  CAS  Google Scholar 

  15. Khilji FA, Gonzalez M, Finlay AY (2002) Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 147(Suppl 62):50

    Google Scholar 

  16. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM (2000) Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 43:281–285

    Article  PubMed  CAS  Google Scholar 

  17. Krueger G, Koo J, Lebwhol M, Menter A, Stern R, Rolstad T (2001) The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137:280–284

    PubMed  CAS  Google Scholar 

  18. Krueger GG, Langley RG, Finlay AY, Griffiths CEM, Woolley JM, Lalla D, Jahreis A (2005) Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 153:1192–1199

    Article  PubMed  CAS  Google Scholar 

  19. Langley RG, Ellis CN (2004) Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 51:563–569

    Article  PubMed  Google Scholar 

  20. McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CEM, Van Assche D (2003) Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 149:323–331

    Article  PubMed  CAS  Google Scholar 

  21. Mease PJ, Menter MA (2006) Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 54:685–704

    Article  PubMed  Google Scholar 

  22. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W (2005) Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141:31–38

    Article  PubMed  CAS  Google Scholar 

  23. Menter A, Griffiths CEM (2007) Current and future management of psoriasis. Lancet 370:272–284

    Article  PubMed  CAS  Google Scholar 

  24. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K (2008) Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58:106–115

    Article  PubMed  Google Scholar 

  25. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41:401–407

    Article  PubMed  CAS  Google Scholar 

  26. Reich K, Mrowietz U (2007) Treatment goals in psoriasis. J Dtsch Dermatol Ges 5:566–574

    Article  PubMed  Google Scholar 

  27. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CEM (2005) Infliximab induction and maintenence therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367–1372

    Article  PubMed  CAS  Google Scholar 

  28. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo CA, Li S, Dooley LT, Griffiths CEM (2006) Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 154:1161–1168

    Article  PubMed  CAS  Google Scholar 

  29. Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CEM (2007) Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol 17:381–386

    PubMed  CAS  Google Scholar 

  30. Revicki D, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M (2008) Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 216:260–270

    Article  PubMed  Google Scholar 

  31. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A (2008) Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 158:549–557

    Article  PubMed  CAS  Google Scholar 

  32. Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C (2008) Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 58:224–231

    Article  PubMed  Google Scholar 

  33. Sampogna F, Tabolli S, Soderfeldt B, Axtelius B, Aparo U, Abeni D (2006) Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 154:844–849

    Article  PubMed  CAS  Google Scholar 

  34. Schmitt JM, Ford DE (2006) Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 213:102–110

    Article  PubMed  Google Scholar 

  35. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA (2006) The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 4:71

    Article  PubMed  Google Scholar 

  36. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD, British Association of Dermatologists (2005) British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153:486–497

    Article  PubMed  CAS  Google Scholar 

  37. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 367:29–35

    Article  PubMed  CAS  Google Scholar 

  38. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473–483

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statements

K. Reich has served as an advisor and paid speaker for Abbott, Biogen-Idec, Centocor, Schering-Plough, Merck-Serono, and Wyeth.

Christopher EM Griffiths has served as a paid advisor or speaker or has received research grants from Abbott, Novartis, Merck-Serono, Centocor, Wyeth, Schering-Plough, and UCB Pharma.

Author information

Authors and Affiliations

  1. Dermatologikum Hamburg, Stephansplatz 5, 20354, Hamburg, Germany

    Kristian Reich

  2. Dermatological Sciences, University of Manchester, Manchester, UK

    Christopher E. M. Griffiths

Authors
  1. Kristian Reich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher E. M. Griffiths
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristian Reich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reich, K., Griffiths, C.E.M. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 300, 537–544 (2008). https://doi.org/10.1007/s00403-008-0885-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-008-0885-7

Keywords

Search

Navigation